Sanofi (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Pfizer (United States)美国8
2. Sanofi (France)法国8
3. Bristol-Myers Squibb (United States)美国5
4. Boehringer Ingelheim (Germany)德国3
5. AstraZeneca (United Kingdom)英国3
6. London School of Hygiene & Tropical Medicine英国3
7. Eli Lilly (United States)美国3
8. United States Food and Drug Administration美国3

按月发文

逐年被引

最新文献

1. 1
   A population-based survey of self-reported and IIEF-defined erectile dysfunction among adult men in the United States in 2021BMC Public Health20257
2. 2
   Real‐World Data and Real‐World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences ( CIOMS ) Working Group XIIIPharmacoepidemiology and Drug Safety202529
3. 3
   Evaluating the Accuracy of Responses by Large Language Models for Information on Disease EpidemiologyPharmacoepidemiology and Drug Safety20258
4. 4
   Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) ConferenceDrug Safety20254
5. 5
   Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargineExpert Opinion on Drug Safety20241
6. 6
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
7. 7
   Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory TherapyDrug Safety202418
8. 8
   Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksDrug Safety20230
9. 9
   Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksDrug Safety202215
10. 10
    Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21BMC Public Health20225

高被引文献

1. 1
   Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directionsPharmacoepidemiology and Drug Safety2020117
2. 2
   Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase®Drug Safety202081
3. 3
   Recommendations for benefit–risk assessment methodologies and visual representationsPharmacoepidemiology and Drug Safety201678
4. 4
   Real‐World Data and Real‐World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences ( CIOMS ) Working Group XIIIPharmacoepidemiology and Drug Safety202529
5. 5
   Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsDrug Safety202129
6. 6
   Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistPharmacoepidemiology and Drug Safety201528
7. 7
   Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records dataPharmacoepidemiology and Drug Safety202125
8. 8
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
9. 9
   Comparison of text processing methods in social media–based signal detectionPharmacoepidemiology and Drug Safety201918
10. 10
    Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory TherapyDrug Safety202418

主要发表期刊

研究主题